This SEC Form 6-K reveals AstraZeneca's Phase III results for Gefurulimab in treating gMG, highlighting significant improvements in daily living activities and a solid safety profile.
Explore AstraZeneca's latest report on anselamimab's Phase III trial for AL amyloidosis, highlighting key findings and future steps.
AstraZeneca PLC announces the approval of Datroway for advanced EGFR-mutated lung cancer, highlighting clinical trial success and strategic collaboration with Daiichi Sankyo.
AstraZeneca's 6-K filing reveals EU approval for Calquence in CLL, showcasing superior trial results and market potential.
AstraZeneca's report highlights Imfinzi's EU approval for muscle-invasive bladder cancer, showcasing significant efficacy from clinical trials. Key insights reveal its potential to redefine treatment standards.
AstraZeneca's latest SEC Form 6-K reveals promising results from the DESTINY-Breast11 trial, highlighting Enhertu's potential to redefine treatment for high-risk HER2-positive breast cancer patients.
Discover AstraZeneca's financial report on Calquence's EU approval for untreated CLL, highlighting significant trial results and market potential.
AstraZeneca's SEC report reveals the discontinuation of the CAPItello-280 trial for mCRPC. Discover the reasons, trial details, and future strategies in prostate cancer treatment.
Discover the pivotal findings from AstraZeneca's DESTINY-Breast09 trial, showcasing Enhertu's potential in HER2-positive metastatic breast cancer and its impact on patient care.
Discover how AstraZeneca's Imfinzi, approved for resectable NSCLC, offers new hope with a 32% reduced recurrence risk, transforming patient care in Europe.
Evaxion Biotech A/S files Form 6-K on Feb 25, 2025, announcing an extension of its EVX-01 cancer vaccine trial. Key for growth and market positioning in biotech.
Explore Cogent Biosciences' Q4 2023 financial results, highlighting significant net losses, cash position, and strategic recommendations for investors.